Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | MMP8 | P22894 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.44 |
| ▸ | NPY1R | P25929 | 1/20 | 0.43 |
| ▸ | NPY2R | P49146 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12677778 | 0.97 | TDP1 (0.55) | TDP1L3MBTL1MAPK1TSHRMMP8 | |
| SCHEMBL18355825 | 0.93 | TDP1 (0.50) | TDP1L3MBTL1MAPK1TSHRMMP8 | |
| SCHEMBL5321935 | 0.91 | TDP1 (0.67) | TDP1L3MBTL1MAPK1TSHRMMP8 | |
| SCHEMBL7412568 | 0.91 | TDP1 (0.49) | TDP1L3MBTL1MAPK1TSHRMMP8 | |
| SCHEMBL21480002 | 0.90 | TDP1 (0.48) | TDP1L3MBTL1MAPK1TSHRMMP8 | |
| SCHEMBL5857539 | 0.90 | TDP1 (0.61) | TDP1L3MBTL1MAPK1TSHRMMP8 | |
| SCHEMBL16826227 | 0.88 | TDP1 (0.59) | TDP1L3MBTL1MAPK1TSHRMMP8 | |
| SCHEMBL3290933 | 0.88 | TDP1 (0.59) | TDP1L3MBTL1MAPK1TSHRMMP8 | |
| SCHEMBL31356497 | 0.87 | TDP1 (0.56) | TDP1L3MBTL1MAPK1TSHRLMNA | |
| SCHEMBL7429704 | 0.87 | TDP1 (0.61) | TDP1L3MBTL1MAPK1TSHRMMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3730590-B1 | LIQUID CRYSTAL MEDIA WITH HOMEOTROPIC ALIGNMENT | MERCK PATENT GMBH (DE) | 2025-12-24 | — | — | EP | disclosed |
| US-20250221996-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BEIGENE, LTD. (KY) | 2025-07-10 | — | — | US | disclosed |
| EP-3784750-B1 | LIQUID CRYSTAL MIXTURE AND LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2022-06-15 | — | — | EP | disclosed |
| EP-3730590-A1 | LIQUID CRYSTAL MEDIA WITH HOMEOTROPIC ALIGNMENT | Merck Patent GmbH (DE) | 2020-10-28 | — | — | EP | disclosed |
| EP-3730590-A1 | LIQUID CRYSTAL MEDIA WITH HOMEOTROPIC ALIGNMENT | Merck Patent GmbH (DE) | 2020-10-28 | — | — | EP | disclosed |
| EP-2918658-B1 | Liquid crystalline media with homeotropic alignment | MERCK PATENT GMBH (DE) | 2020-05-13 | — | — | EP | disclosed |
| EP-2918658-B1 | Liquid crystalline media with homeotropic alignment | MERCK PATENT GMBH (DE) | 2020-05-13 | — | — | EP | disclosed |
| US-10513657-B2 | Liquid-crystalline media having homeotropic alignment | MERCK PATENT GMBH (DE) | 2019-12-24 | — | — | US | disclosed |
| US-10513657-B2 | Liquid-crystalline media having homeotropic alignment | MERCK PATENT GMBH (DE) | 2019-12-24 | — | — | US | disclosed |
| US-20180057743-A1 | LIQUID-CRYSTALLINE MEDIA HAVING HOMEOTROPIC ALIGNMENT | MERCK PATENT GMBH (DE) | 2018-03-01 | — | — | US | disclosed |
| US-6573378-B1 | 9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine having a purity of greater than 95% by weight or it's sodium salt | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2003-06-03 | — | — | US | disclosed |
| US-6458772-B1 | Prodrugs | MEDIVIR AB (SE) | 2002-10-01 | — | — | US | disclosed |
| EP-1123935-A2 | 3'-Fluorinated guanosine derivatives for the treatment or prophylaxis of HBV or retroviral infections | MEDIVIR AB (SE) | 2001-08-16 | — | — | EP | disclosed |
| EP-0988304-B1 | NUCLEOSIDES ANALOGUES, SUCH AS ANTIVIRALS INCLUDING INHIBITORS OF RETROVIRAL REVERSE TRANSCRIPTASE AND THE DNA POLYMERASE OF HEPATITIS B VIRUS (HBV) | MEDIVIR AB (SE) | 2001-05-02 | — | — | EP | disclosed |
| EP-0988304-A1 | NUCLEOSIDES ANALOGUES, SUCH AS ANTIVIRALS INCLUDING INHIBITORS OF RETROVIRAL REVERSE TRANSCRIPTASE AND THE DNA POLYMERASE OF HEPATITIS B VIRUS (HBV) | MEDIVIR AB (SE) | 2000-03-29 | — | — | EP | disclosed |
| WO-1999009031-A1 | NUCLEOSIDES ANALOGUES, SUCH AS ANTIVIRALS INCLUDING INHIBITORS OF RETROVIRAL REVERSE TRANSCRIPTASE AND THE DNA POLYMERASE OF HEPATITIS B VIRUS (HBV) | MEDIVIR AB (SE) | 1999-02-25 | — | — | WO | disclosed |
| WO-1995022330-A1 | ANTIVIRAL AGENTS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 1995-08-24 | — | — | WO | disclosed |
| US-5075445-A | GUANINE DERIVATIVES | BEECHAM GROUP P.L.C. (GB) | 1991-12-24 | — | — | US | disclosed |
| EP-0141927-B1 | ANTIVIRAL GUANINE DERIVATIVES | BEECHAM GROUP PLC (GB) | 1991-10-30 | — | — | EP | disclosed |
| EP-0141927-A2 | Antiviral guanine derivatives | BEECHAM GROUP PLC (GB) | 1985-05-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250221996-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | KRAS, NRAS, HRAS | TDP1 2773/4885L3MBTL1 3358/4885MAPK1 649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.